Members of the Rabies-018 V49_23E1 study group: Martin Alberer (Institute of Infectious Diseases and Tropical Medicine, LMU Klinikum, Munich, Germany), Silja Bühler (Division of Hygiene and Infectious Diseases, Institute of Hygiene and Environment, Hamburg, Germany), Johanna Fischer-Herr (Bernhard Nocht Centre for Clinical Trials [BNCCT], Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany), Christoph Hatz (Swiss Tropical and Public Health Institute, Basel, Switzerland), Kristina Huber (Institute of Infectious Diseases and Tropical Medicine, LMU Klinikum, Munich, Germany), Micha Löbermann (Department of Tropical Medicine and Infectious Diseases, Rostock University Medical Center, Rostock, Germany), Michael Ramharter (Bernhard Nocht Centre for Clinical Trials [BNCCT], Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany), Daniela Rogler (Epidemiology, Biostatistics and Prevention Institute [EBPI], Zürich, Switzerland), Angelika Wagner (Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria), and Ines Zwazl (Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria). All members of the Rabies-018 V49_23E1 study group were involved in the planning, conduct, and/or reporting of the work described in the article. We are indebted to all the Investigators, to all the study personnel and to all the study participants for their continuous commitment over a period of 10 years from the original primary vaccination study throughout this extension study. We are also grateful to Giovanna Curreli (GSK) and Gábor Belák (GSK) for their support in study-related activities, Daria Rudenko for monitoring activities, and Bavarian Nordic. The authors would like to thank the Akkodis Belgium platform for writing and editorial assistance (by Sara-Teodora Vulcu), manuscript coordination, and design support, on behalf of GSK.